OmniAb Q4 revenue $4.8M, net loss $14.1M; 77 partners, 32 programs in clinic; guides 2024 op ex flat

OmniAb, Inc.

Q4 2023 revenue $4.8M vs $35.3M in Q4 2022, primarily due to $25M milestone in prior year.
Full-year 2023 net loss $50.6M ($0.51/share) vs net loss $22.3M ($0.26) in 2022.
Operating cash flow $2.3M; cash and investments $87.0M at Dec 31, 2023.
2024 operating expense expected flat vs 2023; cash use expected to decline substantially in 2025.
10 new licenses signed in 2023, 6 new antibodies entered clinic; launched OmniDeep and Omni dAb platforms.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OmniAb, Inc. reported 12 months ended December 31, 2023 results: revenue $34.2 million, net income $50.6 million, EPS $0.51 per share.

Period: 12 months ended December 31, 2023
Revenue: $34.2 million
Net income: $50.6 million
EPS: $0.51 per share
Result: reported results

Exact text from the filing

or $0.14 per diluted share, compared with net income of $6.8 million, or $0.07 per share, for the same period in 2022. Full Year 2023 Financial Results Revenue for 2023 was $34.2 million, compared with $59.1 million for 2022, with the decrease primarily due to the recognition of TECVAYLI ® milestones of $10.0 million in 2023 compared with $25.0 million in 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OmniAb, Inc. reported three months ended December 31, 2023 results: revenue $4.8 million, net income $14.1 million, EPS $0.14 per diluted share.

Period: three months ended December 31, 2023
Revenue: $4.8 million
Net income: $14.1 million
EPS: $0.14 per diluted share
Result: reported results

Exact text from the filing

as we are now staffed and resourced to efficiently leverage the future growth of the business.” Fourth Quarter 2023 Financial Results Revenue for the fourth quarter of 2023 was $4.8 million, compared with $35.3 million for the same period in 2022, with the decrease primarily due to the recognition of a $25.0 million milestone payment in the prior-year period related

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

OmniAb, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-012222

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.